Orchestra BioMed Holdings, Inc. (OBIO)

Orchestra BioMed Holdings Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020
Net Income	-49.12	-33.61	-23.01	-21.36
Depreciation & Amortization	0.92	0.79	0.18	0.14
Share-Based Compensation	7.63	3.38	0.3	0.22
Other Operating Activities	-5.55	0.15	3.1	-5.19
Operating Cash Flow	-46.13	-29.29	-19.43	-26.18
Capital Expenditures	-0.08	-0.59	-0.27	-0.54
Acquisitions	0	0	-0.21	-0.19
Change in Investments	10.77	-63.53	13.5	27.69
Investing Cash Flow	10.69	-64.12	13.02	26.97
Share Issuance / Repurchase	0.25	110.03	0.01	0
Debt Issued / Paid	-10.85	3.55	-4	10
Other Financing Activities	56.81	-10.33	-	-
Financing Cash Flow	46.22	103.26	-3.99	10
Net Cash Flow	10.78	9.85	-10.41	10.78
Free Cash Flow	-46.21	-29.88	-19.7	-26.72
Free Cash Flow Margin	-1674.09%	-845.74%	-	-468.56%
Free Cash Flow Per Share	-1.39	-1.99	-2.23	-13.27

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).